Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Septerna, Inc.NASDAQ: SEPN
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q3 FY2026 operating expenses of $46.11M rose 144.2% year over year, ahead of the +70.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 5.8% from the prior quarter.
Context
- Operating expenses amounted to 275.8% of revenue in FY2025, down 7342.6 pp from a year earlier.
- Operating expenses increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth of +144.2% holds above the trailing-twelve-month pace of +70.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 126.75M USD
- Year-over-year change
- +54.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 126.75M | +54.8% |
| FY2024 | 2024-12-31 | 81.9M | +4356.7% |
| FY2023 | 2023-12-31 | (1.92M) | — |
Operating Expenses vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 operating expenses of $169.24M is the 2nd highest of the 7 companies compared; the peer median is $155.4M.
- Its year-over-year change of +70.9% is the 2nd highest of 6, against a peer median of +30.0%.
- Operating expenses amounts to 175.8% of revenue for SEPN, versus a peer median of 435.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $256.85M | +16.9% | +75.4% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $169.24M | +70.9% | — | 175.8% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $160.33M | +76.4% | +57.4% | — |
KLRAKailera Therapeutics, Inc. | FY2025 | $158.34M | — | — | — |
| LTM Mar 2026 | $152.46M | +30.0% | +8.2% | 762.3% | |
| LTM Mar 2026 | $65.98M | -50.3% | -1.5% | — | |
| LTM Mar 2026 | $39.88M | +59.2% | +10.1% | 108.3% | |
| Peer median (excluding SEPN) | $155.4M | +30.0% | +10.1% | 435.3% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 151K | 1.08M | 45.95M |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 151K | 1.08M | 45.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% |
| Research & Development | 35.98M | 65.34M | 97.58M |
| Selling, General & Admin | 9.72M | 16.56M | 29.16M |
| Operating Expenses | (1.92M) | 81.9M | 126.75M |
| Depreciation & Amortization | 848K | 1.4M | 1.6M |
| EBITDA | (44.7M) | (70.9M) | (47.26M) |
| EBITDA Margin | -29604.0% | -6594.9% | -102.9% |
| Operating Income | 2.08M | (80.82M) | (80.8M) |
| Operating Margin | 1374.2% | -7518.4% | -175.8% |
| Interest Income | 2.79M | 8.62M | 19.53M |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2.8M | 8.53M | 31.93M |
| Income Before Tax | 4.87M | (72.3M) | (48.87M) |
| Pre-Tax Margin | 3225.8% | -6725.2% | -106.3% |
| Income Tax Expense | 691K | (498K) | 12K |
| Net Income | 4.18M | (71.8M) | (48.88M) |
| Net Margin | 2768.2% | -6678.9% | -106.4% |
| EPS (Basic) | 0.03 | (1.93) | (1.10) |
| EPS (Diluted) | 0.03 | (1.93) | (1.10) |
| Weighted Avg Shares | 19.5M | 37.19M | 44.26M |
| Weighted Avg Shares (Diluted) | 19.5M | 37.19M | 44.26M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.